Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival

American Journal of Hematology

Volumn 85, Issue 1, 2010, Pages 51-56

  Han, Xuesong ^a   Zheng, Tongzhang ^a   Foss, Francine M ^b   Lan, Qing ^c   Holford, Theodore R ^a   Rothman, Nathaniel ^c   Ma, Shuangge ^a   Zhang, Yawei ^a  

^a YALE UNIVERSITY   (United States)

^b YALE CANCER CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; CYTOCHROME P450 2E1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; ARYLAMINE ACETYLTRANSFERASE; GLUTATHIONE S-TRANSFERASE T1; GLUTATHIONE TRANSFERASE; GSTP1 PROTEIN, HUMAN; ISOENZYME; N ACETYLTRANSFERASE 1; N-ACETYLTRANSFERASE 1;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; DEMOGRAPHY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; GENOTYPE; KAPLAN MEIER METHOD; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; REGISTER; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ARYLAMINE N-ACETYLTRANSFERASE; CONNECTICUT; CYTOCHROME P-450 CYP2E1; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; ISOENZYMES; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, FOLLICULAR; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; YOUNG ADULT;

EID: 74049114631     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21580     Document Type: Article

References (43)

1. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK, editors. SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute. Available at: http://seer. cancer.gov/csr/1975-2005/. Last accessed on 2008.
2. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265-276.
3. Clarke C, O'malley C.Non-Hodgkin lymphoma. In: Ries LAG,Yong JL,Keel GE,Eisner MP,Lin YD,Horner M-JD, editors. Cancer Survival Among Adults: US SEER Program, 1988-2001, Patient and Tumor Characteristics. Bethsda, MD: National Cancer Institutes, SEER Program, NIH; 2007. pp 235-242, Chapter 28.
4. Han X, Kilfoy B, Zheng T, et al. Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. Cancer Causes Control 2008;19:841-858.
5. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
6. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159-2169.
7. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947.
8. Al-Dayel F, Al-Rasheed M, Ibrahim M, et al. Polymorphisms of drug-metabolizing enzymes CYP1A1, GSTT and GSTP contribute to the development of diffuse large B-cell lymphoma risk in the Saudi Arabian population. Leuk Lymphoma 2008;49:122-129.
9. Gra OA, Glotov AS, Nikitin EA, et al. Polymorphisms in xenobiotic-metabolizing genes and the risk of chronic lymphocytic leukemia and non-Hodgkin's lymphoma in adult Russian patients. Am J Hematol 2008;83:279-287.
10. De Roos AJ, Gold LS, Wang S, et al. Metabolic gene variants and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 2006;15:1647-1653.
11. Sarmanova J, Benesova K, Gut I, et al. Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas. Hum Mol Genet 2001;10:1265-1273.
12. Soucek P, Sarmanova J, Kristensen VN, et al. Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas. Int Arch Occup Environ Health 2002;75(Suppl):S86-S92.
13. Skibola CF, Bracci PM, Paynter RA, et al. Polymorphisms and haplotypes in the cytochrome P450 17A1, prolactin, and catechol-O-methyltransferase genes and non-Hodgkin lymphoma risk. Cancer Epidemiol Biomarkers Prev 2005;14:2391-2401.
14. Kerridge I, Lincz L, Scorgie F, et al. Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk. Br J Haematol 2002;118: 477-481.
15. Rollinson S, Levene AP, Mensah FK, et al. Gastric marginal zone lymphoma is associated with polymorphisms in genes involved in inflammatory response and antioxidative capacity. Blood 2003;102:1007-1011.
16. Wu MS, Shun CT, Huang SP, et al. Effect of interleukin-1beta and glutathione S-transferase genotypes on the development of gastric mucosa-associated lymphoid tissue lymphoma. Haematologica 2004;89:1015-1017.
17. Chiu BC, Kolar C, Gapstur SM, et al. Association of NAT and GST polymorphisms with non-Hodgkin's lymphoma: A population-based case-control study. Br J Haematol 2005;128:610-615.
18. Dieckvoss BO, Stanulla M, Schrappe M, et al. Polymorphisms within glutathione S-transferase genes in pediatric non-Hodgkin's lymphoma. Haematologica 2002;87:709-713; discussion 713.
19. Morton LM, Schenk M, Hein DW, et al. Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma. Pharmacogenet Genomics 2006;16:537-545.
20. Morton LM, Holford TR, Leaderer B, et al. Alcohol use and risk of non-Hodgkin's lymphoma among Connecticut women (United States). Cancer Causes Control 2003;14:687-694.
21. Zhang Y, Holford TR, Leaderer B, et al. Hair-coloring product use and risk of non-Hodgkin's lymphoma: A population-based case-control study in Connecticut. Am J Epidemiol 2004;159:148-154.
22. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89:3909-3918.
23. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.
24. SEER Limited-Use 1973-2004-ASCII Text Data: Surveillance, Epidemiology, and End Results (SEER) Program. Limited-Use Data (1973-2004), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Available at: www.seer.cancer.gov. Last accessed on April 2007.
25. Lan Q, Zheng T, Shen M, et al. Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma. Hum Genet 2007;121: 161-168.
26. Zhang Y, Hughes KJ, Zahm SH, et al. Genetic variations in xenobiotic metabolic pathway genes modify the relationship between personal hair dye use and risk of non-Hodgkin lymphoma. Am J Epidemiol 2009;170:1222-1230.
27. Carlson CS, Eberle MA, Rieder MJ, et al. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004;74:106-120.
28. Packer BR, Yeager M, Burdett L, et al. SNP500Cancer: A public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucl Acids Res 2006;34:D617-D621.
29. Hein DW, Doll MA, Fretland AJ, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000;9:29-42.
30. Hein DW. N-acetyltransferase 2 genetic polymorphism: Effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 2006;25:1649-1658.
31. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
32. Guengerich FP, Kim DH, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991;4:168-179.
33. Marks BD, Smith RW, Braun HA, et al. A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic vivid p450 substrate. Assay Drug Dev Technol 2002;1:73-81.
34. Stanulla M, Schrappe M, Brechlin AM, et al. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: A case-control study. Blood 2000;95:1222-1228.
35. Hohaus S, Mansueto G, Massini G, et al. Glutathione-S-transferase geno-types influence prognosis in follicular non-Hodgkin's Lymphoma. Leuk Lymphoma 2007;48:564-569.
36. Singhal SS, Saxena M, Ahmad H, Awasthi YC. Glutathione S-transferase of mouse liver: Sex-related differences in the expression of various isozymes. Biochim Biophys Acta 1992;1117:105.
37. Butera L, Feinfeld DA, Bhargava M. Sex differences in the subunits of glutathione-S-transferase isoenzyme from rat and human kidney. Enzyme 1990; 43:175-182.
38. Blair IA. Endogenous glutathione adducts. Curr Drug Metab 2006;7:853-872.
39. Daniel V. Glutathione S-transferases: Gene structure and regulation of expression. Crit Rev Biochem Mol Biol 1993;28:173-207.
40. Adam PJ, Berry J, Loader JA, et al. Arylamine N-acetyltransferase- 1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol Cancer Res 2003;1:826-835.
41. Ashton LJ, Murray JE, Haber M, et al. Polymorphisms in genes encoding drug metabolizing enzymes and their influence on the outcome of children with neuroblastoma. Pharmacogenet Genomics 2007;17:709-717.
42. Morton LM, Holford TR, Leaderer B, et al. Cigarette smoking and risk of non-Hodgkin lymphoma subtypes among women. Br J Cancer 2003;89:2087-2092.
43. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2007 Sub (1973-2005 varying)-Linked To County Attributes-Total U.S., 1969-2005 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Available at: www.seer.cancer.gov. Last accessed on April 2008.